▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #62 by analyst upside · 2026-11-12
EYPT
EyePoint, Inc.
Healthcare · Market Cap $30M · P/E 0x
ANALYST PRICE TARGET
+2266.1%
implied upside to consensus target
Current Price $0.36
Consensus Target $8.44
Bull Target $31.0
Bear Target $0.5
Analysts Covering 8
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
1
Hold
6
Sell
1
52-Week Low $0.33
52-Week High $19.11
YTD Return -97.9%
FUNDAMENTALS
Market Cap $30M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.38
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $3M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.33
52-Week High $19.11
Current Price $0.36
Bear Target $0.5
Bull Target $31.0
● Now $0.36 ● Target $8.44
TRADING DATA
Avg Volume 9.3M
YTD Return -97.9%
Analyst Count 8
Consensus Hold
Upside to Target +2266.1%
Last Updated 2026-11-12

ANALYST SUMMARY

EyePoint, Inc. (EYPT) is currently trading at $0.36 with a Wall Street consensus price target of $8.44, implying potential upside of 2266.1% over the next 12 months. 8 analysts currently cover EYPT, with a consensus rating of Hold - 12% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $31.0, while the most cautious has a target of $0.5.

EYPT operates in the Healthcare sector with a market capitalisation of $30M. The stock is down 97.9% year-to-date and is currently trading near the lower end of its 52-week range of $0.33 – $19.11.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

TOVX +2386.0%
Theriva Biologics, Inc.
$7M · P/E 0.2x · Buy
REVB +3030.7%
Revelation Biosciences, Inc.
$2M · P/E 0.1x · Buy
DWTX +1086.4%
Dogwood Therapeutics, Inc.
$45M · P/E 0.1x · Strong Buy
ETST +1036.4%
Earth Science Tech, Inc.
$25M · P/E 8.8x · Hold
VXRT +800.9%
Vaxart, Inc.
$90M · P/E 2.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for EYPT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Laidlaw & Co. ↓ Downgrade
Buy → Hold 2026-10-20 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-10-20 Building track record
Guggenheim ↓ Downgrade
Buy → Neutral 2026-10-20 62% win rate (8 calls)
JP Morgan ↓ Downgrade
Neutral → Underweight 2026-10-20 43% win rate (7 calls)
HC Wainwright & Co. reit
Neutral → Neutral 2026-10-20 31% win rate (48 calls)
TD Cowen ↓ Downgrade
Buy → Hold 2026-09-02 Building track record
Citigroup - Reiterated
Buy → Buy 2026-08-18 Building track record
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2026-08-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
19
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →